Recce Pharmaceuticals Unveils Strategic Focus on Synthetic Anti-Infectives

Story Highlights
Recce Pharmaceuticals Unveils Strategic Focus on Synthetic Anti-Infectives

Recce Pharmaceuticals Ltd. ( (AU:RCE) ) has issued an update.

Recce Pharmaceuticals Ltd has released a corporate presentation detailing its focus on developing and commercializing synthetic anti-infectives. The presentation outlines the company’s strategic intentions and future plans, although it emphasizes that these are subject to various risks and uncertainties. The company disclaims any responsibility for the accuracy or completeness of the information provided, and it does not constitute an offer to sell or buy securities.

More about Recce Pharmaceuticals Ltd.

Recce Pharmaceuticals Ltd is a company operating in the pharmaceutical industry, focusing on the commercialization of a new class of synthetic anti-infectives. The company is listed on the Australian Securities Exchange (ASX) under the ticker RCE and also on the Frankfurt Stock Exchange (FSE) under the ticker R9Q.

YTD Price Performance: -16.67%

Average Trading Volume: 131,159

Technical Sentiment Consensus Rating: Buy

Current Market Cap: A$92.75M

See more insights into RCE stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App